Regeneca recalls specific lot of RegenArouse
Regeneca has issued a voluntary nationwide recall of RegenArouse, lot number 130100, as it contains a drug not listed on the label.
Tadalafil is an FDA-approved drug used as treatment for male erectile dysfunction (ED).
The active drug ingredient is not listed on the label for these products.
Tadafil could interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.
RegenArouse, lot number 130100, is a pink capsule sold individually in foil packets, with the expiration date of 12/5/2013 and a UPC code of 816860010079.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250